Prostate carcinoma

This early-phase trial tests whether an experimental DNA vaccine (pTVG-HP) combined with the immunotherapy drug nivolumab and targeted radiation can help the immune system attack prostate cancer that has returned in a few spots. The study involves 14 men whose cancer has come bac…

This study tests whether using a special PET scan (PSMA-PET) to guide radiation can reduce short-term side effects in men whose prostate cancer returns after surgery. About 54 men will receive targeted radiation to the pelvis plus a boost to spots seen on the scan, along with sta…

This phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…

This study compares a new boost approach called irreversible electroporation (IRE) using the NanoKnife system against the standard radiation boost for men with intermediate-risk prostate cancer. All participants will receive standard stereotactic body radiation therapy (SBRT), bu…

This phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get …

This study tests a new way to deliver radiation therapy for early-stage prostate cancer. Instead of two separate sessions days apart, both radiation doses are given just three hours apart on the same day. The goal is to see if this is safe and could make treatment more convenient…

This study tests a gene therapy called aglatimagene besadenovec, given with valacyclovir, in 45 men with intermediate-risk prostate cancer who will also receive radiation. The main goal is to see how the therapy spreads in the body and to measure immune responses and tumor marker…

This trial tests whether wrapping the nerves around the prostate with a special tissue allograft during surgery can reduce erectile dysfunction and incontinence. 25 men with localized prostate cancer will receive the wrap during nerve-sparing prostate removal. The study focuses o…

This study tests a combination of two drugs—pembrolizumab (an immunotherapy) and 177Lu-PSMA-617 (a targeted radiation therapy)—in men with advanced prostate cancer that has stopped responding to hormone treatments. The goal is to see if this combo can slow or stop cancer growth. …

This early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA…

This study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…

This study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…

This study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control PSA levels in men whose prostate cancer has returned after initial treatment. About 65 participants will receive either enzalutamide alone or both drugs for 3 months, wit…

This study is for men whose prostate cancer has come back in a few spots after radiation, but is still hormone-sensitive. Researchers want to see if adding a 12-month course of hormone therapy (ELIGARD) to targeted treatments like radiation or surgery helps keep the cancer from g…

This early-phase study tests two experimental drugs (JNJ-87189401 and JNJ-78278343) that help the immune system attack prostate cancer cells. The study involves about 355 men with advanced prostate cancer. The main goal is to find the safest dose and check for side effects.

This study tests two types of targeted radiation therapy (177Lu-PSMA-617 and 225Ac-PSMA-617) in 45 men with high-risk prostate cancer who are scheduled for prostate removal surgery. The goal is to see which therapy delivers more radiation to the tumor and how it affects the immun…

This study tests a new way to give radiation therapy for advanced prostate cancer. Instead of many sessions, patients get just 5 high-dose treatments. The goal is to see if this shorter approach is safe and works well. About 70 people with high-risk prostate cancer will take part…

This phase II trial tests a new radiation technique for low to intermediate risk prostate cancer. It uses an MRI-guided 'microboost' to deliver a higher dose to the tumor while lowering the dose to the rest of the prostate. The goal is to see if this approach is safe and causes f…

This study looks at two ways to protect the heart and metabolism in men with prostate cancer who are on hormone therapy (ADT). ADT can increase the risk of heart problems. The study compares time-restricted eating (a form of intermittent fasting) and two GLP-1 drugs (semaglutide …

This study tests whether adding the experimental drug mevrometostat to the standard treatment enzalutamide can slow down cancer growth better than enzalutamide alone. It involves 1000 men with metastatic prostate cancer that still responds to hormone therapy. Participants will be…

This phase 3 trial is testing whether adding low-intensity shockwave therapy to standard erectile dysfunction pills helps men recover erectile function more effectively after robotic prostate cancer surgery. The study involves 158 men who have undergone nerve-sparing surgery and …

This early-stage trial is testing a drug called xaluritamig, given alone or with a hormone blocker, before men with intermediate- or high-risk prostate cancer have their prostate removed. The main goal is to see if the treatment is safe and does not interfere with surgery. About …

This phase 2 trial tests whether a personalized walking program can slow the progression of localized prostate cancer in men who are on active surveillance (monitoring instead of immediate treatment). The 36 participants will exercise up to 5 times per week for 225-300 minutes to…

This trial tests whether a newer, single-port robotic surgery for prostate cancer can match or beat the standard multi-port approach in helping men recover sexual function. About 480 men with localized prostate cancer will be randomly assigned to one of the two procedures. Resear…

This Mayo Clinic trial is testing a procedure called MRI-guided TULSA for men with low to intermediate grade prostate cancer. It uses high-energy sound waves guided by MRI to precisely destroy tumor cells, aiming to avoid surgery or radiation. The study will enroll 100 men aged 4…

This study is testing whether adding a focused radiation boost after standard short-course radiotherapy improves outcomes for men with localized prostate cancer. About 1,200 men will be randomly assigned to receive either standard SBRT alone or SBRT plus one of three boost method…

This clinical trial is for men with prostate cancer that has spread to nearby pelvic lymph nodes but not further. It compares two radiation strategies: one that gives a higher dose to the prostate only, and another that boosts both the prostate and the affected lymph nodes. All p…

This study tests whether a 16-week home-based high-intensity interval training (HIIT) program can slow prostate cancer in Black men who are on active surveillance (monitoring the cancer without immediate treatment). The trial involves 68 participants who will use a stationary bik…

This study tests whether stem cells from donated fat tissue can help men recover erectile function after surgery for localized prostate cancer. Forty men aged 40 to 70 will receive either stem cells or a placebo during or after their prostate removal. The goal is to see if the tr…

This study tests a three-part program to increase the use of precision oncology—genetic testing that guides personalized treatment—for veterans with advanced lung or prostate cancer. The program includes a patient education video, feedback to doctors on their testing patterns, an…

This study is testing a new type of radiation therapy that adapts to changes in the prostate and bladder during each treatment session. It is for men with localized prostate cancer who also have an enlarged prostate or urinary symptoms. The goal is to see if this approach can red…

This study tests a new robot-assisted surgery for localized prostate cancer that leaves the full length of the urethra intact. The goal is to help men regain urinary continence faster after prostate removal. About 60 men with early-stage prostate cancer will undergo the procedure…

This trial tests whether focal ablation—using extreme cold (cryotherapy) or high-intensity ultrasound (HIFU)—can effectively destroy prostate tumors while leaving healthy tissue unharmed. It enrolls men with early-stage, localized prostate cancer that shows up on MRI. The goal is…

This study tests a high-dose radiation implant (brachytherapy) for men whose prostate cancer returned after standard external beam radiation. About 30 participants will receive this targeted treatment to the exact spot of recurrence, identified by advanced MRI. The goal is to con…

This phase 2 trial tests whether giving prostate cancer radiation in just 2 sessions is as safe and effective as the standard 5-session approach. About 100 men with low- or intermediate-risk prostate cancer will be randomly assigned to one of the two schedules. Both groups will u…

This study tests whether adding the drug niraparib to standard hormone therapy after radiation helps control high-risk prostate cancer that hasn't spread far. About 200 men will receive either hormone therapy alone or hormone therapy plus niraparib. The goal is to see if the comb…

This study tests a new way to deliver high-dose radiation to prostate tumors using real-time MRI guidance. It includes two groups: men whose prostate cancer has returned after prior radiation, and men with advanced cancer receiving standard external beam radiation plus this boost…

This study tests whether curcumin, a natural compound found in turmeric, can slow or stop the progression of low-risk prostate cancer in men who are not receiving immediate treatment. About 291 men with early-stage prostate cancer will take either curcumin or a placebo daily for …

This phase 2 trial is testing three different drugs—abiraterone acetate, enzalutamide, and apalutamide—in 192 veterans with castrate-sensitive prostate cancer that has spread. The goal is to see which drug works best as a first treatment when combined with hormone therapy. Resear…

This Phase 3 trial is testing whether adding pelvic radiotherapy to standard hormone therapy can delay cancer progression in men whose prostate cancer has spread to nearby lymph nodes after prostate removal surgery. About 372 participants will be randomly assigned to receive eith…

This study tests whether a new type of radiation seed, called DaRT, can be safely placed inside the prostate to treat cancer that has returned after initial treatment. Up to 10 men with non-metastatic, locally recurrent prostate cancer will receive the seeds. The main goal is to …

This study tests whether giving radiation to the para-aortic lymph nodes (located in the abdomen) can better control prostate cancer that has returned in a limited number of spots. Men with hormone-sensitive prostate cancer and up to five lesions seen on a PSMA PET/CT scan will r…

This phase 2 trial is testing whether combining focal prostate ablation (a surgery that destroys only the cancerous part of the prostate) with a short course of hormone therapy can effectively treat intermediate-risk prostate cancer. The study will enroll 57 participants and meas…

This study tests a procedure called irreversible electroporation (IRE) using the NanoKnife system to treat intermediate-risk prostate cancer. The goal is to destroy cancer cells with fewer side effects than standard treatments like surgery or radiation. About 100 men over age 50 …

This phase 2 trial is testing whether the immunotherapy drug atezolizumab, alone or combined with etrumadenant or tocilizumab, can boost immune cell activity in prostate tumors before surgical removal. About 68 men with localized prostate cancer will receive treatment before radi…

This study is testing a new way to give radiation for high-risk prostate cancer that has not spread. One hundred men will receive a shorter, stronger radiation boost to the prostate along with standard pelvic radiation. The goal is to see if this approach is safe and does not cau…

This study tests a laser treatment guided by MRI to destroy early-stage prostate cancer in men aged 40-80 with low to intermediate risk. The goal is to control the cancer and avoid more aggressive treatments like surgery or radiation. Researchers will check results with follow-up…

This study tests several new drug combinations for men with advanced prostate cancer that has spread. The experimental drugs include QLC5508 (a targeted therapy that delivers a toxin to cancer cells) and QLH12016 (a drug that breaks down the male hormone receptor). These are comb…

This study tests whether freezing only the part of the prostate that contains cancer (focal cryotherapy) can control intermediate-risk prostate cancer. About 30 men with a single area of cancer will receive this targeted treatment. The goal is to reduce side effects while keeping…

This trial is testing whether combining the drug Pluvicto with precise radiation (SBRT) can lower the chance of cancer returning in men with locally advanced prostate cancer, while also reducing the need for long-term hormone therapy. About 45 participants will receive one to thr…

This trial tests a type of internal radiation called high-dose-rate brachytherapy for men with early-stage prostate cancer. The goal is to see if focusing radiation only on the tumor can control the cancer while causing fewer urinary and sexual problems than standard treatments. …

This study tests whether testosterone replacement therapy (TRT) is safe and beneficial for men with low testosterone and early-stage prostate cancer who are on active surveillance. Researchers will track cancer progression, quality of life, and whether men stay on active surveill…

This study tests an internet-based program called iLIVE that combines weight loss coaching and online exercise classes for men who have had hormone therapy for prostate cancer. The goal is to see if it can reduce obesity and frailty, which are common side effects of treatment. Re…

This study tests if axelopran, a drug used for opioid-induced constipation, can slow tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for up to a year. Res…

This study tests a treatment that uses lasers and a light-sensitive drug to destroy cancer cells in the prostate without major surgery. It is for men whose prostate cancer has returned after radiation therapy and who cannot have surgery or more radiation. The goal is to see if th…

This study is testing a new, shorter radiation treatment for men with early-stage prostate cancer. Instead of the usual 5 sessions, doctors will give 3 high-dose radiation treatments. The goal is to see if this approach is safe and causes fewer side effects while still controllin…

This study is testing ablative therapies—treatments that destroy cancer cells with heat or cold—for men with localized prostate cancer. Researchers want to see how well these treatments control cancer and affect quality of life, including urinary and sexual function. The study wi…

This study for veterans with prostate cancer that has returned in a few spots (oligorecurrence) compares standard systemic therapy alone versus standard therapy plus PET-directed local treatment using surgery or radiation. The goal is to see if adding local therapy delays the can…

This trial tests whether giving radiation every other day (5 sessions total) is as safe as the standard daily schedule (20 sessions) for men who have had prostate cancer surgery. The study involves 204 participants across multiple centers. The main goal is to see if the shorter s…

This study is testing a new, shorter way to treat prostate cancer using proton therapy. Instead of the usual 5 sessions, researchers want to see if just 2 sessions are as safe and effective. The goal is to make treatment faster and more affordable while keeping side effects low. …

This study tests a new way to deliver radiation for intermediate-risk prostate cancer. Using an MRI machine that also delivers radiation, doctors can give a higher dose to the main tumor while lowering the dose to the rest of the prostate. The goal is to improve tumor control and…

This study is for people with advanced prostate cancer that has spread and stopped responding to standard treatments. It compares the usual fixed schedule of 6 doses of Lu-PSMA therapy to a flexible schedule that allows up to 12 doses with breaks (treatment holidays) based on how…

This phase 2 trial tests whether taking simvastatin, a common cholesterol drug, for 8 weeks before prostate surgery can improve the immune system's ability to fight prostate cancer. Half of the 36 men with localized prostate cancer will receive the drug, while the other half will…

This study tests a precise type of radiation therapy (MRgRT) that aims to protect the nerves and blood vessels needed for erections in 70 men with low- or intermediate-risk prostate cancer. Participants receive 5 high-dose radiation sessions guided by MRI. The goal is to see if t…

This early-phase trial is testing whether taking two hormone-blocking pills—relugolix and enzalutamide—before and after standard radiation or surgery can help cure high-risk locally advanced prostate cancer. About 46 men will participate to first find a safe dose, then see if the…

This study compares two different hormone therapy combinations (leuprolide plus abiraterone vs. relugolix plus abiraterone) in men with advanced prostate cancer who are also receiving radiation therapy. The goal is to see which combination causes less damage to the heart and bloo…

This study tests whether adding precise, high-dose radiation (SBRT) to standard hormone therapy can delay cancer progression in men with prostate cancer that has spread to 1-3 spots. About 118 participants will be randomly assigned to get SBRT plus standard care or standard care …

This study tests a precise type of radiation called proton therapy for men with high-risk prostate cancer that has spread to lymph nodes. The goal is to see if targeting the tumor and nearby lymph nodes with protons causes fewer bowel and urinary side effects than standard radiat…

This early-phase trial is testing whether a second, highly targeted dose of radiation (SBRT) can safely treat prostate cancer that has returned after initial radiation therapy. The study involves 36 men whose cancer is confined to a small area of the prostate. The main goal is to…

This phase 2 trial tests a new radiation approach for men with high-risk or locally advanced prostate cancer. It combines hypofractionated radiotherapy (fewer, larger doses) with a microboost that delivers extra radiation to the most aggressive tumor spots. The goal is to improve…

This early-phase trial is testing whether a combination of two hormone-blocking drugs (darolutamide and relugolix) can safely shrink high-risk prostate tumors before they are surgically removed. About 30 men with aggressive prostate cancer will take the drugs for a short time bef…

This early-phase trial is testing whether giving epigenetic therapy before prostate removal can make the cancer more visible to the immune system. About 20 men with high-risk prostate cancer will receive the drugs before their scheduled prostatectomy. The main goals are to check …

This early-phase trial is testing a new way to deliver radiation for low-to-intermediate risk prostate cancer. Instead of many sessions, it uses just two high-dose treatments, with an extra boost to the main tumor. The goal is to see if this approach is safe and feasible for abou…

This study tests whether adding the drug talazoparib to standard hormone therapy can better control advanced prostate cancer that still responds to hormone treatment. About 70 men with cancer that has spread will receive the combination. The goal is to see if this approach lowers…

This phase II trial is testing whether using a special PET/MR scan (PSMA) to guide radiation therapy can improve outcomes for men with high-risk prostate cancer. Fifty participants will receive targeted radiation boosts to areas identified by the scan. The main goal is to see if …

This trial is testing two improvements to standard radiation therapy for men with high-risk prostate cancer. First, it adds a higher radiation dose (a boost) directly to the visible tumor inside the prostate, aiming to reduce the chance of cancer spreading. Second, it compares gi…

This study is testing a new way to deliver radiation for prostate cancer that adapts to daily changes in the body. It involves 100 men with low- or intermediate-risk prostate cancer. The goal is to see if this approach can better protect nearby organs and improve quality of life.

This study tests a new, less invasive way to treat intermediate-risk prostate cancer using a laser guided by micro-ultrasound. The goal is to see if the procedure is safe and can delay or avoid the need for more aggressive treatments like surgery or radiation. Seven men aged 40-8…

This early-phase study is testing whether adding metformin and turmeric to standard hormone therapy can help control prostate cancer that is starting to grow again. About 34 men with rising PSA levels will take these supplements alongside their usual treatment. Researchers will t…

This study is testing whether giving only 3 doses of high-precision radiation (SBRT) over 3 days is as safe and effective as the usual 5-dose schedule for men with low or intermediate risk prostate cancer. The radiation is guided by a special catheter that acts like a GPS, tracki…

This study tests a new type of radiation therapy for prostate cancer that uses an MRI machine to guide the beam in real time. The goal is to deliver high doses of radiation more precisely to the tumor while sparing healthy tissue. The trial will enroll 50 men with localized or li…

This early-stage trial is testing two experimental drugs together in men with advanced prostate cancer that has worsened after standard hormone therapy. HS-20093 is an antibody-drug conjugate that targets a protein on cancer cells, while HRS-5041 is a drug that breaks down androg…

This study tests whether adding two drugs—fasudil hydrochloride and a PD-1 inhibitor—to standard hormone therapy before prostate cancer surgery can better shrink or eliminate tumors. About 83 men with locally advanced or limited metastatic prostate cancer will receive either the …

This Phase 2 trial tests whether adding homoharringtonine, a drug from a plant, to standard hormone therapy can better shrink or eliminate prostate cancer before surgery. About 96 men with locally advanced or limited spread prostate cancer will receive either the drug combo or a …

This study tests whether a very short course of radiation (5 days) is as safe and effective as a longer course (2-3 weeks) for men with localized prostate cancer. All participants also receive a brachytherapy boost. The main goal is to compare side effects and quality of life ove…

This phase 2 trial is testing whether a special PET scan tracer called 18F-DCFPyL can accurately show how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive the tracer and undergo PET/CT scans at s…

This study tests whether a new type of ultrasound, called transperineal micro-ultrasound, can better detect prostate cancer during biopsy. Unlike standard ultrasound, this method uses higher frequency sound waves to create clearer images. Researchers will enroll 138 men scheduled…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study compares a new artificial intelligence (AI) system to radiologists for reading prostate MRI scans to detect cancer. About 130 men who are already scheduled for a prostate biopsy will have their MRI read by both the AI and a radiologist. The goal is to see if the AI can…

This study will test whether a special type of scan called PSMA PET/MRI can find prostate cancer that comes back after a treatment called High-Intensity Focused Ultrasound (HIFU) better than a standard MRI. About 60 men who had HIFU for prostate cancer will get both scans one yea…

This study is testing whether a new flexible MRI coil can accurately detect significant prostate cancer in 258 men with intermediate or high-risk disease. The goal is to see if this less invasive approach can reduce the number of unnecessary biopsies. Participants will receive bo…

This Phase 3 trial is testing whether combining a special PET scan (PSMA PET) with MRI can detect prostate cancer better than standard methods. About 204 men with suspected prostate cancer will receive the combined imaging, and results will be compared to biopsy findings. The goa…

This trial tests whether combining a radioactive tracer (18F-rhPSMA-7.3) with PET and multiparametric MRI can better identify clinically significant prostate cancer than MRI alone. Men suspected of having prostate cancer will receive the tracer and undergo imaging before a target…

This study is testing whether new MRI techniques and artificial intelligence can improve how doctors diagnose prostate cancer. Researchers will enroll 275 men with suspected or confirmed prostate cancer. The goal is to make diagnosis more accurate and less invasive than current m…

This study tests whether a special PET-MRI scan using a radioactive tracer called rhPSMA-7.3 can find higher-risk prostate cancer that standard tests might miss. Men with low-risk or favorable intermediate-risk prostate cancer who are candidates for active surveillance will recei…

This study compares a newer PSMA PET scan to the standard MRI for staging prostate cancer in men eligible for focal therapy (treatment that targets only the tumor). About 138 men with early-stage prostate cancer will be randomly assigned to get the PSMA PET scan or not. The goal …

This phase 2 trial tests whether a radioactive tracer called 64Cu-DOTA-AE105 can accurately show the aggressiveness of prostate cancer on a PET scan. About 168 men with low- to intermediate-risk prostate cancer will receive the tracer and undergo imaging. The goal is to see if th…

This early-phase trial is testing whether a special MRI scan, using hyperpolarized pyruvate and urea, can better detect high-grade prostate cancer that is still confined to the prostate. About 80 men scheduled for prostate removal will receive an IV of these substances before ima…

This study tests whether a combined PET/MRI scan using a radioactive tracer can accurately detect if prostate cancer has spread to nearby lymph nodes. Fifty men with high-risk localized prostate cancer will receive the scan before their planned prostate removal surgery. The resul…

This early trial is testing whether a special PET/CT scan using flotufolastat F-18 can better guide prostate biopsies than standard MRI. The study will enroll 30 men with suspicious MRI findings. Researchers will compare how often the new method detects aggressive prostate cancer…

This study tests a new way to do PET scans for men with high-risk prostate cancer. Instead of two full CT scans, it uses one CT plus a delayed PET-only image, which may lower radiation exposure. Researchers will check if the delayed images match the standard ones well enough. The…

This phase II trial is testing whether a special PET/CT scan using flotufolastat F 18 can accurately find prostate cancer that remains or returns after focal therapy (such as laser or freezing). The study will enroll 81 men who had focal therapy 6 to 36 months ago. If the scan wo…

This early study tests whether a special PET scan using 18F-fluciclovine can find prostate cancer that doesn't show up well on standard PSMA scans. The study will include 30 men with advanced prostate cancer that either has low PSMA levels or has changed into a more aggressive ne…

This trial tests whether a walking program can reduce signs of colorectal cancer in men who had pelvic radiation for prostate cancer. Radiation can raise the risk of colon cancer years later by causing mutations and inflammation. Researchers will compare colon tissue and blood sa…

This study explores whether aerobic exercise, like walking, can lower levels of ctDNA (a marker of cancer in the blood) and help prevent breast, prostate, or colorectal cancer from coming back. Researchers will test different amounts of weekly exercise (90 to 375 minutes) in 33 p…

This trial tests whether an electronic health record alert can encourage primary care doctors to have informed discussions about PSA screening with men at higher risk for prostate cancer. The alert does not mandate screening but prompts a conversation about individual risk factor…

This study will compare how men with intermediate-risk prostate cancer feel about their quality of life after either total prostate removal (surgery) or a less invasive treatment called focal HIFU (high-intensity focused ultrasound). About 100 sexually active men aged 40-75 will …

This study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This early study tests whether a gel called Barrigel can stay unfrozen and protect the rectum during prostate cancer cryoablation (freezing treatment). About 20 men with localized or recurrent prostate cancer will receive the gel before the procedure. The main goal is to see if t…

This study looks at whether a special low-field MRI scanner can give clearer images for prostate cancer radiation therapy in people who have both hips replaced. Standard MRI often creates blurry images around metal implants, making it hard to aim the radiation precisely. The rese…

This phase III trial tests whether an automated planning tool called RapidPlan can match or beat human-driven planning for prostate cancer radiation therapy. About 108 men with prostate cancer will be randomly assigned to one of two planning methods. The goal is to see if the aut…

This study tests a web-based program called TEMPO designed to help men with prostate cancer and their caregivers cope with anxiety and improve physical activity. About 376 patient-caregiver pairs will be randomly assigned to use TEMPO or simply monitor their anxiety for 12 weeks.…

This study tests whether a supervised golf exercise program can improve physical function, mental health, and quality of life in prostate cancer survivors who are on hormone therapy. Twenty men aged 55-85 with little or no golf experience will participate. The program includes wa…

This study tests whether personalized nutrition and exercise plans can reduce frailty and improve body composition in prostate cancer survivors who are on hormone therapy (ADT). Fifty participants will receive diet advice, exercise coaching, and educational sessions. Researchers …

This study tests whether two home-based exercise programs—walking or high-intensity cycling—can improve fitness and reduce fatigue in men with metastatic prostate cancer who are starting hormone therapy. Twenty-four participants will exercise at home for 12 weeks, with remote mon…

This study tests whether exercising with others, including some social time, can reduce feelings of loneliness in older men (65+) who have had prostate cancer. 150 participants will be assigned to one of three groups: socially enhanced group exercise, regular group exercise, or e…

This study compares giving standard prostate cancer treatment at home versus in a clinic for Black men with advanced or metastatic prostate cancer. The goal is to see if home treatment improves patient satisfaction, safety, and reduces stress. Thirty-eight participants will recei…

This study tests whether oxybutynin, a medication used for overactive bladder, can help men recover urinary control sooner after robotic prostate removal for prostate cancer. About 135 participants will take either the drug or a placebo daily for up to 3 months. Researchers will …

This study tests a telehealth program called ENGAGE for people with stage IV breast, prostate, lung, or colorectal cancer. The program helps manage symptoms like pain, fatigue, and distress that interfere with daily life. About 190 participants will be randomly assigned to ENGAGE…

This study tests whether a single dose of NPX-5 (a psilocybin drug) combined with talk therapy can reduce severe anxiety in people who have trouble adjusting to a cancer diagnosis. About 87 adults aged 18–80 with moderate-to-severe anxiety will receive one of three doses (25 mg, …

This early-phase study tests whether a weight-loss drug called tirzepatide can help overweight or obese men with intermediate-risk prostate cancer lose weight before their prostate removal surgery. The study will enroll 30 participants and focus on safety and how well the program…

This study tests a new feature on the da Vinci 5 surgical robot that gives surgeons a sense of touch during prostate cancer surgery. 60 patients will take part, with surgeons randomly using the force feedback on or off. The goal is to see if this helps surgeons learn faster and r…

This trial compares two types of radiation therapy for low-risk prostate cancer: SBRT (a precise, high-dose external beam treatment) and low-dose rate brachytherapy (implanting radioactive seeds). The goal is to see which causes fewer urinary and bowel side effects and leads to a…

This trial tests whether using daily MRI or CT scans to adjust radiation plans in real time can lower side effects for men with localized prostate cancer. 186 participants will receive standard stereotactic body radiation therapy (SBRT) either with or without daily plan adaptatio…

This study tests a drug called fezolinetant, already approved for hot flashes in menopausal women, to see if it can reduce hot flashes in men with prostate cancer who are on hormone-lowering therapy. About 32 men will take the drug daily for 28 days. The goal is to measure how mu…

This study tests whether light therapy and occupational therapy can reduce fatigue in people with genitourinary cancers (like prostate, kidney, or bladder cancer). About 224 adults on active cancer treatment will be assigned to receive light therapy, occupational therapy, both, o…

This study tests a technique called 'Spot Delete' during pencil beam scanning proton therapy for low- and intermediate-risk prostate cancer. The goal is to reduce side effects like diarrhea, rectal bleeding, and urinary problems by preventing proton beams from stopping in sensiti…

This phase 2 trial tests whether wearing bright white light glasses can reduce fatigue and improve mood in men with advanced prostate cancer who are on hormone therapy. The study will compare immediate use of the light therapy to delayed use in 210 participants. The goal is to he…

This trial compares two different schedules of MRI-guided radiation for men with low or favorable intermediate risk prostate cancer. One group gets the standard five sessions, the other gets just two sessions. The goal is to see if the shorter course can maintain cancer control w…

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that might explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treat…

This study looks at whether artificial intelligence (AI) can help radiologists find prostate cancer on MRI scans. About 150 men aged 55-80 who are scheduled for a prostate biopsy will take part. The AI software will be compared to radiologists reading the scans alone. The goal is…

This study is gathering medical records and imaging data from 10,000 men with prostate cancer or at high risk. Researchers aim to find patterns in scans that could help diagnose and treat the disease more effectively. No new drugs or procedures are being tested.

This study is collecting blood, urine, tissue samples, and health information from 300 men with advanced prostate cancer. Researchers hope to build a resource that will help them learn more about the disease and improve future care. Participants will not receive any experimental …

This study looks at how bacteria in the gut and urine change in men with prostate cancer who are getting hormone therapy and radiation. Researchers will collect stool and urine samples from 30 participants to see if these bacteria affect healing and side effects. The goal is to f…

This study is creating a database to track what happens to men with localized prostate cancer who choose cryotherapy (freezing the tumor). Researchers will record side effects and how long it takes for PSA levels to rise again. Up to 1,000 men will be followed over time to gather…

This study looks at how well a short course of hormone therapy (ADT) works in men with high-risk prostate cancer that hasn't spread. Researchers use a special PET/CT scan to measure changes in cancer activity before and after treatment. About 50 men will take part, and they will …

This study collects tissue and blood samples from 1,500 people with prostate or bladder cancer that has come back or spread. Researchers will analyze the samples to find genetic changes and other markers that may explain why some cancers stop responding to treatment. The goal is …

This study will follow 300 men with early-stage prostate cancer who choose to be treated with high-intensity focused ultrasound (HIFU). Researchers will collect data on side effects, cancer control, and urinary and sexual function over time. The goal is to better understand how w…

This study tests whether a new online tool, called BeSpoke, helps men with newly diagnosed localized prostate cancer make better treatment decisions. The tool gives personalized information about different treatments and their likely outcomes. Researchers will compare men who use…

This study tests a new imaging technique called low-count quantitative SPECT (LC-QSPECT) to see how the drug Radium-223 spreads in men with advanced prostate cancer. About 38 men who are already eligible for Radium-223 will get extra scans after their treatment. The goal is to se…

This early-stage study is testing a radioactive imaging agent called 99mTc-PSMA-I&S in 30 men with prostate cancer who are scheduled for lymph node removal surgery. The goal is to see how well this agent can help surgeons detect cancer that has spread to the lymph nodes during th…

This study looks at whether special breathing exercises can help the brains of people with multiple sclerosis or cancer, as well as their caregivers. Researchers will use MRI scans to see how breathing affects oxygen flow in the brain. The goal is to understand the connection bet…

This study is looking for better ways to detect prostate cancer early in men who have a high genetic risk. Researchers will test urine samples and PSA levels in 200 men aged 35-70 with certain gene mutations. The goal is to see if these tests can predict aggressive prostate cance…

This study is looking at how common low vitamin D levels are among Black men with prostate cancer, and whether vitamin D supplements can improve their immune function. Researchers will measure vitamin D and immune markers in blood samples before and after supplementation. The goa…

This study is figuring out what normal PSA levels are for trans women and non-binary people who have a prostate. Researchers will measure PSA in 500 volunteers aged 40 and older who are on hormones or have had lower surgery. The goal is to help doctors better detect prostate canc…

This study is testing whether a new genetic test (called PCAI ImmunoScore) can predict how well men with high-risk prostate cancer will respond to the drug darolutamide before surgery. About 100 participants will take darolutamide for 3-4 months, then have their prostate removed.…

This study is for men with intermediate- or high-risk prostate cancer who will receive hormone therapy and radiation. Researchers want to see if using a special PET scan (PSMA PET) during hormone therapy can help doctors better target remaining cancer with radiation while avoidin…

This study follows men with low-risk prostate cancer who have chosen active surveillance—monitoring the cancer over time rather than treating it right away. Researchers will collect data for years to learn which signs predict that the cancer may become aggressive. The goal is to …

This study looks for better ways to find aggressive prostate cancer early in people who have a genetic risk. Researchers will collect blood, urine, and tissue samples from 450 participants to learn more about the genetics of this disease. The goal is to improve future screening a…

This study aims to improve treatment for aggressive prostate cancer by growing 3D mini-tumors from patient samples in the lab. Researchers will compare two techniques to see which better predicts how a patient's cancer will respond to radiation or drugs. The goal is to help docto…

This study is developing and testing an educational tool to help men aged 65 and older with prostate cancer decide with their doctors whether to reduce the frequency of follow-up tests like biopsies. The tool is being tested with 45 participants, including patients, caregivers, a…

This study follows 64 men with localized prostate cancer who undergo laparoscopic radical prostatectomy (keyhole surgery to remove the prostate). The goal is to track any complications that occur from the day of surgery up to 30 days later. By understanding how often problems hap…

This study compares regular MRI scans to standard care for men with low- to medium-risk prostate cancer who choose active surveillance (monitoring instead of immediate treatment). The goal is to see if MRIs can detect cancer progression earlier and more accurately, potentially re…

This study looks at how to help veterans with advanced prostate cancer make informed decisions about precision oncology tests, which use genetic information to guide cancer care. Researchers will develop and test a decision support tool to reduce confusion and address racial gaps…

This study at Mayo Clinic is testing new AI-based image processing techniques (AIR Recon DL and Sonic DL) to see if they can make MRI scans faster and clearer for detecting pelvic abnormalities like endometrial and prostate cancer. Researchers will compare the new methods to stan…

This study involves 30 men with advanced prostate cancer who will receive two different PET scans (PSMA and FDG) to see how their tumors behave at different stages and during treatment. The goal is not to treat the cancer directly, but to gather information that could help doctor…

This study is for men with localized prostate cancer who are scheduled for surgery to remove the prostate. Participants will take hydroxychloroquine (a drug used for malaria) or a placebo daily before surgery. The goal is to see how the drug affects certain cell processes in the …

This study looks at how a type of radiation called HDR brachytherapy changes prostate cancer on a molecular level. Researchers will analyze blood, tissue, and gut bacteria samples from 100 men with low-risk or early intermediate-risk prostate cancer. The goal is to find the best …

This study sets up Community Living Labs at American Legion posts to help Black men access prostate health services and education. Researchers will see if these labs improve knowledge, screening, and trust. About 250 people, including community health workers and advisors, will t…

This study looks at anxiety levels in men with low-risk prostate cancer who are closely monitored instead of receiving immediate treatment, and also checks how their partners are doing. Researchers will use questionnaires to measure anxiety and find out what factors might predict…

This study tests whether an online self-monitoring platform helps patients with lung, colorectal, breast, or prostate cancer track medication safety events and concerns while taking oral anticancer drugs at home. Eighty adult patients currently on active cancer treatment will use…

This study looks at how a week of either eating less or exercising daily affects prostate tumor growth and muscle health in 45 men with prostate cancer. Participants will be assigned to a reduced-calorie diet, daily exercise with mild diet changes, or their usual routine. After 7…

This study is testing whether removing fewer lymph nodes during prostate cancer surgery is as safe and effective as removing more. Researchers will compare two groups of 800 men with prostate cancer who are having their prostate removed. One group will have a limited lymph node r…

This study looks at why African American men with prostate cancer often miss out on genetic testing. Researchers are testing whether a community-based health coach can provide clear, culturally relevant education to help these men make informed decisions about testing. The goal i…

This study tests whether giving doctors and patients a report generated by artificial intelligence can improve how well risks and benefits of prostate cancer treatments are discussed. About 283 men with newly diagnosed prostate cancer and their doctors will be randomly assigned t…

This study compares a standard survivorship care plan to one tailored for low health literacy in 150 African American men who have finished treatment for localized or limited-spread prostate cancer. The goal is to see if the tailored plan helps them better understand their follow…

This study tests whether showing surgeons a visual decision-support tool before they meet with patients improves how they discuss risks and benefits of surgery. Up to 20 urologists and 200 patients with prostate or kidney cancer will take part. Researchers will compare conversati…

This study is testing a blood test that looks for tiny pieces of prostate cancer cells floating in the bloodstream. The goal is to see if the number of these cells can tell doctors how advanced the cancer is and if it comes back after surgery. About 200 men with early-stage prost…

This study looks at how hormonal therapy changes PSMA levels in men with prostate cancer, both in early and advanced stages. Researchers will use PSMA PET scans at different times after starting therapy to see when the scan is most accurate for staging the cancer. The goal is to …